Used in the treatment of idiopathic pulmonary fibrosis (IPF), BMS-986020 is a potent and selective antagonist of the lysophosphatidic acid receptor 1 (LPA1). This receptor plays a key role in fibrotic processes by mediating fibroblast recruitment, activation, and extracellular matrix deposition. By blocking LPA1, the compound helps reduce lung tissue scarring and slow disease progression. It has been evaluated in clinical trials to assess its efficacy in improving lung function and patient outcomes in IPF and other fibrotic conditions. Its development represents a targeted approach to treating fibrosis with potential application in systemic sclerosis and liver fibrosis.